[A17-27] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
|2017-09-15||Extract of dossier assessment||343 kB|
|2017-09-15||Dossier assessment (German version)||855 kB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2017-12-07 A G-BA decision was published.